ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Cup-to-disc ratio in GLP-1 RA Associated…

Cup-to-disc ratio in GLP-1 RA Associated Non-Arteritic Anterior Ischemic Optic Neuropathy

Ophthalmology·August 6
OphthalmologyConfirms priorNon-Arteritic Anterior Ischemic Optic NeuropathyRetrospective Case-Control StudyGLP-1 Receptor AgonistAdultOzempicSemaglutide

Summary

View source

What was studied

This retrospective, multi-center case-control study evaluated whether cup-to-disc ratio (CDR) differs between NAION patients with and without GLP-1 RA exposure, and quantified NAION odds by CDR category, using 1,812 unaffected fellow eyes from 2,169 NAION patients (2018–2024) across 16 neuro-ophthalmology centers, compared to 465 controls.

Key findings

CDR did not differ across GLP-1 RA groups (mean CDR ~0.13). Eyes with photo-measured CDR ≤0.20 had 46× greater NAION odds (OR=46.3; 95% CI 23.0–93.4) vs. eyes with CDR >0.40; 54% of NAION fellow eyes had CDR ≤0.20 vs. only 9% of controls (p<0.001).

Study limitations

- Study does not assess whether GLP-1 RA medications are an independent risk factor for NAION — causality cannot be inferred. - CDR was provider-estimated in most cases, with photo-measured CDR available only for a subset, introducing measurement variability. - Retrospective design and reliance on medical records may introduce selection and ascertainment bias.

Clinical implications

Crowded optic discs (CDR ≤0.20) carry a 46-fold increased odds of NAION regardless of GLP-1 RA use — clinicians can use photo-measured CDR to better counsel patients on their baseline NAION risk. GLP-1 RA exposure does not appear to change the disc anatomy risk profile, but this study cannot determine whether these drugs independently raise NAION risk.

Caveats

  • Provider-estimated vs. photo-measured CDR were both used; results based on photo-measurement apply to a subset and may not generalize equally to provider estimates.
  • The brand tag 'Ozempic' is applied as the most recognized semaglutide brand; the paper refers to semaglutide broadly and may include other formulations (e.g., Wegovy, Rybelsus).
  • The sample size of n=2,634 reflects 2,169 NAION patients plus 465 controls; the 1,812 fellow eyes and 465 control eyes are the analyzed units, so the tag approximates total enrolled subjects.
Show all 4
  • This study explicitly does not test whether GLP-1 RAs are an independent NAION risk factor — clinicians should not interpret these findings as exonerating or implicating GLP-1 RA medications in NAION causation.

Related Questions

Explore related topics

What is the evidence that semaglutide causes NAION?How does cup-to-disc ratio predict optic nerve risk in patients starting GLP-1 receptor agonists?Should I screen optic disc anatomy before prescribing GLP-1 agonists to high-risk patients?

Publication Details

Year
2026
Journal
Ophthalmology
Sample Size
n=2,634
Source
View article
Keep scrolling
More content below.
Up Next